Kyowa Hakko Kirin Archives

Kyowa Kirin Announces Marketing Authorisation Application for Istradefylline Validated by European Medicines Agency

Mark McIntyre January 7, 2020 blog

Tokyo, Japan,　January 6th , 2020 — Kyowa Kirin Co., Ltd. (TSE: 4151 President and CEO: Masashi Miyamoto, “Kyowa Kirin”) today announces that its marketing authorisation application (MAA) for istradefylline (KW-6002) as an adjunctive treatment to levodopa-based regimens in adult patients with Parkinson’s disease (PD) experiencing “OFF” time, has been validated by the European Medicines Agency (EMA) and is now under …

Ultragenyx and Kyowa Kirin Announce Health Canada Approval of Crysvita™ (burosumab injection) for the Treatment of X–linked Hypophosphatemia (XLH) in Adults and Children

Dylan Macdonald December 6, 2018 blog

First Approved Treatment for XLH in Canada that Targets the Underlying Cause of this Rare, Hereditary, Lifelong Disease.

Kyowa Hakko Kirin President & CEO, Dr. Nobuo Hanai, visits KKI HQ in Galashiels

Spreng Thomson May 19, 2017 blog

Borders-based specialty pharmaceutical company, Kyowa Kirin International plc (KKI), hosted Dr. Nobuo Hanai, President and Chief Executive Officer of KKI’s parent company, Kyowa Hakko Kirin Co. Ltd., at the company’s head office in Galashiels this week.

Tag Archive

Kyowa Kirin Announces Marketing Authorisation Application for Istradefylline Validated by European Medicines Agency

Ultragenyx and Kyowa Kirin Announce Health Canada Approval of Crysvita™ (burosumab injection) for the Treatment of X–linked Hypophosphatemia (XLH) in Adults and Children

Kyowa Hakko Kirin President & CEO, Dr. Nobuo Hanai, visits KKI HQ in Galashiels

About

Get in touch

Connect